Dormência ou parestesia é observada em cerca de 75% dos pacientes.[3]Dyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018 Jun;93(6):777-93.
https://www.mayoclinicproceedings.org/article/S0025-6196(18)30236-2/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/29866282?tool=bestpractice.com
[4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30.
http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com
[5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63.
http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com
[6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53.
http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com
A prevalência de dor em razão da PDIC em qualquer momento da evolução da doença foi estimada em 46% em uma revisão sistemática.[37]Michaelides A, Hadden RDM, Sarrigiannis PG, et al. Pain in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Pain Ther. 2019 Dec;8(2):177-85.
https://link.springer.com/article/10.1007/s40122-019-0128-y
http://www.ncbi.nlm.nih.gov/pubmed/31201680?tool=bestpractice.com
Praticamente todos os pacientes têm perda sensitiva simétrica distal nas modalidades de fibras grossas e finas.[3]Dyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018 Jun;93(6):777-93.
https://www.mayoclinicproceedings.org/article/S0025-6196(18)30236-2/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/29866282?tool=bestpractice.com
[4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30.
http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com
[5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63.
http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com
[6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53.
http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com
Raramente, os pacientes manifestam somente sintomas sensitivos, normalmente parestesias e disestesias distais.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14959
http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com
[38]Oh SJ, Joy JL, Kuruoglu R. Chronic sensory demyelinating neuropathy: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992 Aug;55(8):677-80.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC489203/pdf/jnnpsyc00493-0043.pdf
http://www.ncbi.nlm.nih.gov/pubmed/1326601?tool=bestpractice.com
[39]Ayrignac X, Viala K, Koutlidis RM, et al. Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity? Muscle Nerve. 2013 Nov;48(5):727-32.
http://www.ncbi.nlm.nih.gov/pubmed/23424105?tool=bestpractice.com
Síndromes sensitivas puras ocorrem em <10% dos pacientes e podem ter uma mistura de fibras grossas e finas ou ocorrem predominantemente em fibras grossas, em que a ataxia sensitiva é a principal manifestação.[38]Oh SJ, Joy JL, Kuruoglu R. Chronic sensory demyelinating neuropathy: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992 Aug;55(8):677-80.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC489203/pdf/jnnpsyc00493-0043.pdf
http://www.ncbi.nlm.nih.gov/pubmed/1326601?tool=bestpractice.com
[39]Ayrignac X, Viala K, Koutlidis RM, et al. Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity? Muscle Nerve. 2013 Nov;48(5):727-32.
http://www.ncbi.nlm.nih.gov/pubmed/23424105?tool=bestpractice.com
[70]Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997 Feb;48(2):321-8.
http://www.ncbi.nlm.nih.gov/pubmed/9040714?tool=bestpractice.com
[71]Bouchard C, Lacroix C, Plante V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology. 1999 Feb;52(3):498-503.
http://www.ncbi.nlm.nih.gov/pubmed/10025777?tool=bestpractice.com
Nas síndromes puramente sensoriais os estudos de condução nervosa (ECN) podem mostrar somente anormalidades leves que não satisfazem os critérios eletrodiagnósticos típicos. Proteína do líquido cefalorraquidiano (LCR) elevada, potenciais evocados somatossensoriais anormais e desmielinização à biópsia de nervo podem estar presentes.[38]Oh SJ, Joy JL, Kuruoglu R. Chronic sensory demyelinating neuropathy: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992 Aug;55(8):677-80.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC489203/pdf/jnnpsyc00493-0043.pdf
http://www.ncbi.nlm.nih.gov/pubmed/1326601?tool=bestpractice.com
[39]Ayrignac X, Viala K, Koutlidis RM, et al. Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity? Muscle Nerve. 2013 Nov;48(5):727-32.
http://www.ncbi.nlm.nih.gov/pubmed/23424105?tool=bestpractice.com